Next Article in Journal
MiRNA Expression in Neuroendocrine Neoplasms of Frequent Localizations
Next Article in Special Issue
Non-Coding RNAs in COVID-19: Emerging Insights and Current Questions
Previous Article in Journal
Long Non-Coding RNA (lncRNA) Roles in Cell Biology, Neurodevelopment and Neurological Disorders
 
 
Commentary

microRNA Heterogeneity, Innate-Immune Defense and the Efficacy of SARS-CoV-2 Infection—A Commentary

by 1,2,3
1
LSU Neuroscience Center, Louisiana State University Health Science Center, New Orleans, LA 70112, USA
2
Department of Ophthalmology, Louisiana State University Health Science Center, New Orleans, LA 70112, USA
3
Department Neurology, Louisiana State University Health Science Center, New Orleans, LA 70112, USA
Academic Editors: Gaetano Santulli and Jessica Gambardella
Non-Coding RNA 2021, 7(2), 37; https://doi.org/10.3390/ncrna7020037
Received: 28 May 2021 / Revised: 7 June 2021 / Accepted: 13 June 2021 / Published: 18 June 2021
(This article belongs to the Collection Non-coding RNAs and COVID-19)
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a member of the genus Betacoronavirus in the family Coronaviridae, possesses an unusually large single-stranded viral RNA (ssvRNA) genome of about ~29,811 nucleotides (nt) that causes severe and acute respiratory distress and a highly lethal viral pneumonia known as COVID-19. COVID-19 also presents with multiple ancillary systemic diseases and often involves cardiovascular, inflammatory, and/or neurological complications. Pathological viral genomes consisting of ssvRNA, like cellular messenger RNA (mRNA), are susceptible to attack, destruction, neutralization, and/or modulation by naturally occurring small non-coding RNAs (sncRNAs) within the host cell, some of which are known as microRNAs (miRNAs). This paper proposes that the actions of the 2650 known human miRNAs and other sncRNAs form the basis for an under-recognized and unappreciated innate-immune regulator of ssvRNA viral genome activities and have implications for the efficiency of SARS-CoV-2 invasion, infection, and replication. Recent research indicates that both miRNA and mRNA abundance, speciation, and complexity varies widely amongst human individuals, and this may: (i) In part explain the variability in the innate-immune immunological and pathophysiological response of different human individuals to the initiation and progression of SARS-CoV-2 infection in multiple tissue types; and (ii) further support our understanding of human biochemical and genetic individuality and the variable resistance of individuals to ssvRNA-mediated viral infection and disease. This commentary will briefly address current findings and concepts in this fascinating research area of non-coding RNA and innate-immunity with special reference to natural host miRNAs, SARS-CoV-2, and the current COVID-19 pandemic. View Full-Text
Keywords: COVID-19; Homo sapien (hsa); messenger RNA (mRNA); microRNA (miRNA); severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) COVID-19; Homo sapien (hsa); messenger RNA (mRNA); microRNA (miRNA); severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
MDPI and ACS Style

Lukiw, W.J. microRNA Heterogeneity, Innate-Immune Defense and the Efficacy of SARS-CoV-2 Infection—A Commentary. Non-Coding RNA 2021, 7, 37. https://doi.org/10.3390/ncrna7020037

AMA Style

Lukiw WJ. microRNA Heterogeneity, Innate-Immune Defense and the Efficacy of SARS-CoV-2 Infection—A Commentary. Non-Coding RNA. 2021; 7(2):37. https://doi.org/10.3390/ncrna7020037

Chicago/Turabian Style

Lukiw, Walter J. 2021. "microRNA Heterogeneity, Innate-Immune Defense and the Efficacy of SARS-CoV-2 Infection—A Commentary" Non-Coding RNA 7, no. 2: 37. https://doi.org/10.3390/ncrna7020037

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop